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INTRODUCTION
The following scene takes place at a common pharmacy
counter.
Pharmacist: “There is a generic formulation of this drug.
Would you like to buy it instead of the brand-name prescription?”
Consumer: “How much would I save if I bought the generic
drug?”
Americans are concerned with the cost of drugs.1 Currently,
America’s health care spending is about $2 trillion, and in ten
years, is expected to roughly double to $4.1 trillion.2 To put that
into perspective, we spend about $7,500 per capita on health care
A PDF version of this Note is available online at http://iplj.net/blog/archives/
volumexx/book1. Visit http://iplj.net/blog/archives for access to the IPLJ archive.
*
J.D. Candidate, Fordham University School of Law, 2010; Ph.D., Biochemistry,
Molecular and Cell Biology, Cornell University, 2007; A.B., Vassar College, 2001.
Many thanks to Professors John J. Normile, Partner at Jones Day, and Brian Coggio,
Senior Principal at Fish & Richardson P.C., for their guidance.
1
See, e.g., Andrew Pollack, Costly Drugs Known as Biologics Prompt Exclusivity
Debate, N.Y. TIMES, July 22, 2009, at B1, available at http://www.nytimes.com/
2009/07/22/business/22biogenerics.html?pagewanted=all.
2
Orrin G. Hatch, U.S. Sen., Remarks Before the U.S. Chamber of Commerce, The
Future of Biologics—Examining Market Competition, Innovation, and Patient Safety
(Apr. 25, 2007), available at http://www.votesmart.org/speech_detail.php?sc_id=279366
&keyword=&phrase=&contain.

GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE)

2009]

FIXING A HOLE

12/30/2009 10:48:32 AM

329

in the United States.3 These figures are expected to rise to $12,800
per capita in 2016.4 Much of this increase is expected because of
greater spending for pharmaceuticals.5 With such a large amount
of national spending invested in healthcare, the millions of
uninsured or solely Medicaid-covered Americans have a great
stake in the price of medication.6 Citizens and legislators are
concerned because “[p]rices are inexorably linked to healthcare,
monetary and fiscal policy, management of national debt, and,
ultimately, overall standard of living.”7 Thus, the rapid rise in
healthcare spending is a deep concern for citizens, drug companies,
healthcare providers, and politicians.8
To bring a new, innovative drug to market, a pharmaceutical
company needs to spend huge sums of money on research and
development.9 Thousands of chemicals are routinely synthesized
in laboratories with the hope that just one chemical will provide a
benefit to Americans.10 Then, labs send the chemical through a
barrage of experimentation for characterization.11 Researchers,
drug companies, and the United States Food and Drug
Administration (“FDA”) need to answer the following questions:
what does this chemical do? And, does this drug generate any
undesirable effects? After years of testing, very few chemicals are

3

Id.
Id.
5
Id.
6
See NLM Gateway, Out-of-Pocket Price, Prescription Medications and Seniors,
http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102275591.html (last visited Aug.
30, 2009).
7
A. Taylor Corbitt, The Pharmaceutical Frontier: Extending Generic Possibilities to
Biologic Therapies in the Biologics Price Competition and Innovation Act of 2007, 18
DEPAUL J. ART TECH. & INTELL. PROP. L. 365, 370 (2008).
8
Id.
9
Joseph A. DiMasi, Ronald W. Hansen & Henry G. Grabowski, The Price of
Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 151, 151
(2003) (“The estimated average out-of-pocket cost per new drug is US$ 403 million
(2000 dollars). Capitalizing out-of-pocket costs to the point of marketing approval at a
real discount rate of 11% yields a total pre-approval cost estimate of US$ 802 million
(2000 dollars).”).
10
U.S. CONG. BUDGET OFFICE, A CBO STUDY: RESEARCH AND DEVELOPMENT IN THE
PHARMACEUTICAL INDUSTRY 2 (2006), available at http://www.cbo.gov/ftpdocs/
76xx/doc7615/10-02-DrugR-D.pdf.
11
Id.
4
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still contenders for FDA approval.12 This tumultuous story of
innovative drug synthesis and testing occurs everyday, as the
industry is constantly looking for the diamond in the rough. As a
result, pharmaceutical companies invest more and more money13
with the hope that after years of work, innovative drugs will allow
them to pay back the deficit caused by research and development.
Few chemicals are able to be considered medicines.14 When an
invention is patented, the inventor must disclose information
permitting others to replicate the invention.15 In return, the
inventor receives the right to exclude others from making, using,
marketing, and offering for sale or importing the invention.16 The
Hatch-Waxman Act,17 which amended the Public Health Service
Act (“PHSA”),18 loosened the exclusivity rights of the patentee by
permitting other pharmaceutical companies to produce identical
chemicals, “follow-on drugs,”19 faster by permitting them to
bypass FDA testing.20 This Act has permitted consumers to
choose between brand-name and generic drugs earlier, driving
down the cost of drugs by price competition.21 However, the drugs
in question have mainly been generated in vitro, in glass tubes.22
12

See DiMasi et al., supra note 9, at 159.
In late 2005, it was estimated that about $95 billion was spent per year on medical
research. Associated Press, $95 Billion a Year Spent on Medical Research, MSNBC,
Sept. 20, 2005, http://www.msnbc.msn.com/id/9407342/.
14
Boehringer Ingelheim, Drug Discovery Process, http://www.boehringeringelheim.com/corporate/research/drug_discovery_process.asp (last visited Sept. 27,
2009) (stating that only one in over a million screened molecules is investigated in late
stage clinical trials and made available to patients).
15
35 U.S.C. § 112 (2006).
16
Id. § 154(a)(1).
17
Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act of 1984,
Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in scattered sections of 15, 21,
28, 35 U.S.C.).
18
Public Health Service Act (PHSA), Pub. L. No. 111-43, 58 Stat. 682 (1944).
19
Follow-on drugs are drugs that are replicated from a non-innovative pharmaceutical
company to compete with the brand-name drug on the market. See Donald Zuhn, Deloitte
White Paper Addresses Unintended Consequences of Follow-on Biologic Regulatory
Pathway, PATENT DOCS, Aug. 27, 2009, http://www.patentdocs.org/2009/08/deloittewhite-paper-addresses-unintended-consequences-of-followon-biologic-regulatorypathway.html.
20
Id.
21
Id.
22
See infra note 39 and accompanying text.
13
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Since the Hatch-Waxman Act was enacted, a new hurdle has
surfaced: should patentees of biologics, or molecules synthesized
in vivo (in cells), also have loosened exclusivity rights?
This Note explores why generic biologics should be tested for
FDA approval as rigorously as brand-name biologics. This Note
argues that the FDA should require the generic companies to
provide experimental data showing that their isolated biological
molecules have the same concentration, purity, potency, and
activity as brand-name biologics.
Part I highlights the legislation that makes drugs available to
the public and examines how biological materials do not fit neatly
into the current legislation. Part II discusses present responses to
the shortcomings of today’s legislation. Finally, Part III offers
prescriptions to manage this healthcare ailment.
I. THE LONG AND WINDING ROAD OF CURRENT AND PENDING
LEGISLATION
The United States is facing a time of change regarding health
care reform.23 There has been a working system in place to permit
the approval of innovative small-molecule drugs, but new
technology does not fit neatly into this system.24 Accordingly, one
must have a comprehensive understanding of current law to best
understand how policies play to the opposing interests of the
innovative and non-innovative pharmaceutical industries.
A. Testing Innovative Drugs
Branded drugs come to the public through innovation. There
are two main parts to the process: research and development, and
clinical testing.25 The pre-clinical phase of development starts
with basic discovery through research, using both in vitro (in glass)
23

The
White
House—Health
Care
Reform,
The
President’s
Plan,
http://www.whitehouse.gov/issues/health_care/ (last visited Sept. 27, 2009) (detailing
President Barack Obama’s health care reform plan).
24
BIO, BIO Principles on Follow-On Biologics, http://www.bio.org/healthcare/
followonbkg/Principles.asp (last visited Oct. 13, 2009).
25
Manthan D. Janodia, Drug Development Process: A Review (Dec. 25, 2007),
http://www.pharmainfo.net/reviews/drug-development-process-review.
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and in vivo (in cells) studies.26 Once researchers identify and
purify a candidate compound27 after screening against a specific
biological target,28 researchers conduct animal studies for further
testing.29
The company developing the drug can file an
Investigational New Drug (“IND”) application after it obtains
positive results from animal studies.30 The FDA then evaluates
INDs and grants permission for the drug to be tested on humans.31
Thus begins the clinical phases of testing, consisting of three
mandatory separate phases.32
Each of these phases weeds out drugs that are not suitable for
general use within the public.33 Phase I clinical trials test for
safety and tolerability of the drug in a small group of human
subjects.34
Phase II trials continue testing for safety and
tolerability, but also assess the preliminary efficacy of the drug in a
much larger pool of volunteers afflicted with the targeted
condition.35 Phase III clinical trials involve the largest pool of
volunteers and are designed to evaluate the drug in a more diverse
population, over a period of several years.36 The drugs that
advance through these three phases are submitted as New Drug
26

Id.
A candidate compound is a chemical that provides a key breakthrough for
consequent clinical trials. Franz F. Hefti, Requirements for a Lead Compound to Become
a Clinical Candidate, BMC NEUROSCIENCE, Dec. 10, 2008, http://www.ncbi.nlm.
nih.gov/pmc/articles/PMC2604885/.
28
The Free Dictionary, Biological Target, http://encyclopedia.thefreedictionary.com/
Biological+target (last visited Sept. 24, 2009) (“A biological target is an enzyme,
receptor or other protein that can be modified by an external stimulus. The definition is
context-dependent and can refer to the biological target of a pharmacologically active
drug compound, or the receptor target of a hormone (like insulin). The implication is that
a molecule is “hit” by a signal and its behavior is thereby changed. This term is
commonly used in pharmaceutical research to describe the native protein in the body that
is modified by a medicinal chemical.”).
29
Hefti, supra note 27.
30
Donna M. Gitter, Innovators and Imitators: An Analysis of Proposed Legislation
Implementing an Abbreviated Approval Pathway for Follow-On Biologics in the United
States, 35 FLA. ST. U. L. REV. 555, 565 (2008).
31
Id.
32
Id.
33
See id. at 565–66.
34
Id. at 565.
35
Id. at 565–66.
36
Id. at 566.
27
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Applications (“NDA”s) and new Biologic License Applications
(“BLA”s) to the FDA.37
B. The Differences Between Drugs and Biologics
Since 1984, pharmaceutical companies have had an easier
opportunity to generate, market, and sell follow-on, or generic,
forms of brand name drugs.38 A drug is generally a small molecule
that is synthesized in vitro.39 Drugs are simple, not requiring any
of the chemical modifications that a cell would provide for
complex proteins.40 A protein, however, is a large organic
molecule that is created in vivo;41 hence, it is called a “biologic
compound” or “biologic.”42 “When two chemically-synthesized
drugs are proven bioequivalent, their safety and efficacy can be
assumed because two identical drugs will consistently produce the
same reactions.
However, biologics do not have such
43
characteristics.”
The structure of a protein is dictated by a series of complex
folding patterns, and is generated as the protein is being
synthesized.44 Additionally, many proteins within the cell also

37

Id.
See Drug Price Competition and Patent Term Restoration Act of 1984, 98 Stat. 1585
(codified at 21 U.S.C. §§ 355, 360cc; 28 U.S.C. § 2201; 35 U.S.C. §§ 156, 271, 282
(2006)).
39
BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 472 (4th ed. 2002). “In
vitro” reactions are carried out in a test tube in the absence of living cells. Id.
40
Ronald A. Rader, Biopharmaceutical Terminology: What is a Biopharmaceutical?
Part I: (Bio) Technology-Based Definitions, BIOEXECUTIVE INT’L, Mar. 2005, at 61–62,
available at http://www.biopharma.com/BioExec_pt1.pdf.
41
ALBERTS ET AL., supra note 39, at 472. “In vivo” reactions take place inside a living
cell. Id.
42
National Cancer Institute, Dictionary of Cancer Terms, http://www.nci.nih.gov/
templates/db_alpha.aspx?CdrID=426407 (last visited Oct. 30, 2009). A biological drug
is “a substance made from a living organism or its products and is used in the prevention,
diagnosis, or treatment of cancer and other diseases.” Id.
43
Kathleen R. Kelleher, FDA Approval of Generic Biologics: Finding a Regulatory
Pathway, 14 MICH. TELECOMM. & TECH. L. REV. 245, 254 (2007).
44
See DAVID L. NELSON & MICHAEL M. COX, LEHNINGER PRINCIPLES OF
BIOCHEMISTRY 159–200 (3d ed. 2000).
38
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require the placement of sugars or fatty acid moieties45 on specific
regions for proper function.46 Because of the complexity of
generating proteins, it is impossible to create proteins using the
same methodology as researchers use to create and mass-produce
drugs.47
Each protein has a highly specific and regulated function
within the cell;48 as such, each protein is required to perform its
intended job perfectly.49 When a protein malfunctions, the
individual cell and the organism suffer.50 For example, when the
cells within the pancreas fail to produce insulin, the person suffers
from Type 1 diabetes mellitus.51 The only way to reverse the
disease is to reintroduce insulin into the person’s body.52 Insulin is
produced within cultured cells, harvested, and purified before
being injected into the patient.53 This illustration reveals how the
specificity of insulin controls a patient’s complete health.54
One can easily characterize small molecules by using
techniques of mass spectrometry, infrared spectrometry, nuclear
magnetic resonance, and x-ray crystallography.55 “However,
larger biologic molecules can be much more difficult to
characterize in detail because they are more variable and

45

The Free Dictionary, Moiety, http://encyclopedia.thefreedictionary.com/moiety (last
visited Oct. 30, 2009). A moiety is a functional group, or part of a molecule, that is
responsible for chemical reactions. See id.
46
NELSON & COX, supra note 44, at 1053–54.
47
Ed Zimney, Understanding Biologics: How They Differ From Drugs and Why They
Cost More, EVERYDAY HEALTH, Dec. 2, 2008, http://www.everydayhealth.com/blog/
zimney-health-and-medical-news-you-can-use/understanding-biologics-how-they-differfrom-drugs-and-why-they-cost-more/.
48
REGINALD H. GARRETT & CHARLES M. GRISHAM, BIOCHEMISTRY 158 (2d ed. 1999).
49
Id.
50
See id. at 159 (“[T]he primary structure facilitates the development of short-range
interactions among adjacent parts of the sequence and also long-range interactions among
distant parts of the sequence.”).
51
MedlinePlus, Diabetes Type 1, http://www.nlm.nih.gov/medlineplus/diabetestype1
.html (last visited Aug. 27, 2009).
52
Janet M. Torpy, Cassio Lynm & Richard M. Glass, Type 1 Diabetes, 298 JAMA
1472, 1472 (1997), available at http://jama.ama-assn.org/cgi/content/full/298/12/1472.
53
The Genetic Landscape of Diabetes, History of Diabetes, http://www.ncbi.nlm.
nih.gov/bookshelf/br.fcgi?book=diabetes&part=A3 (last visited Oct. 31, 2009).
54
Id.
55
Kelleher, supra note 43, at 254.
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complex . . . .”56 While analytical tests can determine structure,
identity, purity, stability, and activity of such complex molecules,
these assays do not determine the safety and efficacy of the
product.57 Therefore, it is currently impossible to accurately
predict the immunogenicity58 of a biologic without using clinical
testing.59
Supplying proteins to repair and save human lives is the new
frontier in pharmaceutical companies.60 Therefore, it is necessary
to determine variability between biologics produced within a
generic pharmaceutical company and a brand name pharmaceutical
company.61 A biologic is generally not a bioequivalent; however,
it can be biosimilar.62
Whereas generics of chemistry-based medicines are
identical copies of the original product, based on a
strict definition of “sameness,” a corresponding
definition cannot be established for biosimilar
medicines because of their nature and the
complexity of their manufacturing process. . . .
Because the manufacturing process of the products
is so complex, extreme care must be taken to ensure
that only medicines which have passed stringent
safety and efficacy assessment, for example
appropriate pre-clinical and clinical tests, are
delivered to patients.63
It is necessary for agencies, such as the FDA, to define the
terms of biosimilarity to best protect the public.
56

Id.
Id. at 254–55.
58
The
Free
Dictionary,
Immunogenicity,
http://medical-dictionary.thefree
dictionary.com/immunogenicity (last visited Oct. 31, 2009). Immunogenicity is “the
property enabling a substance to provoke an immune response, or the degree to which a
substance possesses this property.” Id.
59
Kelleher, supra note 43, at 255.
60
See Biosimilars, Succeeding in the Market of the Future, http://www.pharma
focusasia.com/research_development/biosimilars.htm (last visited Oct. 31, 2009).
61
See id.
62
Id.
63
EUROPABIO, HEALTHCARE BIOTECH FACT SHEET: BIOLOGICAL AND BIOSIMILAR
MEDICINES 3 (2005), available at http://www.europabio.org/documents/FSBiosimilar.pdf.
57
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C. Purifying Enriched Proteins for Use as Biologics
Pharmaceutical companies need to mass-produce recombinant
proteins64 so that they can ultimately purify these proteins to use as
biologics.65 Generating a large quantity of protein is difficult
because protein is produced within cells.66 To gain an appreciation
of how challenging this entire process is, it is necessary to
understand protein synthesis and purification.
Proteins are large macromolecules that are produced within
cells to perform specific functions and are the driving force of
innovative biological research.67 When generating a large quantity
of the desired protein, the targeted protein must be overexpressed68 in a regulated environment to maximize the amount
harvested.69 Researchers introduce recombinant coding DNA
(cDNA) into either prokaryotes (cells without nuclei), or
eukaryotes (nucleated cells).70 E. coli,71 for example, is a
bacterium that can generate a large amount of protein in a short
period of time, but lacks much of the internal machinery to
generate more complex proteins (e.g. proteins modified by a fatty
acid or sugar moiety).72 Many laboratories will first attempt to
over-express proteins in E. coli because it is a simple and robust

64

Recombinant proteins are encoded by recombinant DNA or generated from a
recombinant gene.
Free Online Medical Dictionary, Recombinant Protein,
http://medical-dictionary.thefreedictionary.com/recombinant+protein (last visited Sept.
23, 2009).
65
See CARL BRANDEN & JOHN TOOZE, INTRODUCTION TO PROTEIN STRUCTURE 375 (2d
ed. 1999).
66
Id.
67
GARRETT & GRISHAM, supra note 48, at 107.
68
Over-expression is “excessive expression of a gene by producing too much of its
effect or product.” Merriam-Webster Online, Overexpression, http://www.merriamwebster.com/medical/overexpress (last visited Sept. 23, 2009).
69
See BRANDEN & TOOZE, supra note 65.
70
ALBERTS ET AL., supra note 39, at 491–92.
71
Escherichia coli is a “gram negative bacterium widely used in microbiological and
genetic research as well as in protein production.” Cytos Biotechnology, Glossary of
Biological Terms, http://www.cytos.com/?id=197 (last visited Oct. 31, 2009).
72
See ALBERTS ET AL., supra note 39, at 491–92 (explaining how the normal
replication mechanisms of a virus with recombinant DNA molecules can produce more
than 1,012 identical virus DNA molecules in less than a day, thereby amplifying the
amount of the inserted DNA fragment by the same factor).
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process.73 However, many complex human proteins generated in
E. coli will be inactive due to improper protein folding or the
absence of protein translational modifications (which E. coli does
not have the internal machinery to accomplish).74 Many proteins
must be over-expressed instead in eukaryotic cells to be properly
folded and modified.75 Thus, while scientists have the ability to
introduce cDNA into cells for over-expression, the cells are
ultimately in control and regulate the intracellular process.76
The ability to purify over-expressed functional protein is at the
heart of why generic biologics would be difficult to squeeze into
the Hatch-Waxman Act, which provides companies the
opportunity to produce generic drugs.77 A protein cannot be used
as a biologic when it is still preserved within a cell.78 The
purification process is crucial, as it washes away all other proteins
and cellular debris.79 If the desired protein was not purified before

73

See Jeffrey G. Thomas & Francois Baneyx, Protein Misfolding and Inclusion Body
Formation in Recombinant Escherichia Coli Cells Overexpressing Heat-Shock Proteins,
271 J. BIOLOGICAL CHEMISTRY 11141, 11141 (1996) (“It is well established that the high
level expression of recombinant proteins in Escherichia coli can result in the formation of
insoluble aggregates known as inclusion bodies. Since inclusion bodies consist mainly of
the protein of interest and are easily isolated by centrifugation, their formation has often
been exploited to simplify purification schemes.”).
74
See id. (“Molecular chaperones are a ubiquitous class of proteins that play an
essential role in protein folding by helping other polypeptides reach a proper
conformation or cellular location without becoming part of the final structure.”).
75
See Max-Planck-Innovation, Strategies to Enhance Protein Expression in Eukaryotic
Cells, http://www.max-planck-innovation.de/share/technology/0301-3725-MSGZE_DE.pdf?PHPSESSID=2b61508e0840eeaa5adf0eb9255e5a36 (last visited Oct. 31,
2009).
76
See Bryan A. Liang, Regulating Follow-On Biologics, 44 HARV. J. ON LEGIS. 363,
372 (2007) (listing the possible changes that may occur during a biologic manufacturing
process).
77
Kelleher, supra note 43, at 249.
78
See Theresa Phillips, About.com, Methods for Protein Purification,
http://biotech.about.com/od/protocols/a/ProteinPurify.htm (last visited Oct. 26, 2009)
(“The degree of protein purity required depends on the intended use of the protein. For
some applications, a crude extract is sufficient. However, for other uses, such as in foods
and pharmaceuticals, a high level of purity is required. In order to achieve this, several
protein purification methods are typically used, in a series of purification steps.”).
79
AMERSHAM PHARMACIA BIOTECH, PROTEIN PURIFICATION HANDBOOK 7 (1999),
available
at
http://www.biochem.uiowa.edu/donelson/Database%20items/protein_
purification_handbook.pdf [hereinafter PROTEIN PURIFICATION HANDBOOK] (“The
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being injected into an ailing patient, the patient would suffer much
more than be cured, as such alien proteins would be attacked by
the body.80 The patient would act adversely to such an injection
and, as a result, would develop an immediate and lasting immune
response to all of the unrecognizable proteins introduced into his
body.81 After all, consider that the over-expressed protein was
generated from bacterial or eukaryotic (but non-patient) cells.
Only protein that will not adversely affect the patient can be
introduced into his body.
As protein enrichment and protein purification are crucial to
the generation of biological medicine, it is necessary to gain a solid
understanding of each process. Both the enrichment process and
purification process, which vary significantly for each protein, are
and will be treated by the pharmaceutical corporation as trade
secrets.82 The methodology used to break open the cells, the
solutions used to wash the proteins, and how to separate the
desired protein from the cellular debris are all examples of how
protein purification can be an unpredictable and a highly variable
process.83 Because of this purification process and the uncertainty
of the purity of the proteins, it would be difficult for companies to
replicate brand-name biologics without the necessary trade

development of techniques and methods for protein purification has been an essential
prerequisite for many of the advancements made in biotechnology.”).
80
See Liang, supra note 76, at 375–77 (“[T]here is one central concern for [biologics]
that is not present for chemical medicines: the potential for the product to induce an
adverse immunologic reaction in a patient whose body sees the drug as a foreign invader,
such as a virus or a bacterium. . . . The immunogenicity of biologic drugs appears to be
related to a broad array of factors, including the biologic’s structure, the patient’s genetic
attributes, the type of biologic in question, impurities in the product, the route of
administration, and the frequency of use.”).
81
Id. at 377 (“The human immune response to a biologic product is difficult to predict
generally, and this is even more difficult in the face of changes to manufacturing
processes.”).
82
See Corbitt, supra note 7, at 397–99; see also Kelleher, supra note 43, at 254.
83
PROTEIN PURIFICATION HANDBOOK, supra note 79, at 7 (“Proteins can even be
produced in forms which facilitate their subsequent chromatographic purification.
However, this has not removed all challenges. Host contaminants are still present and
problems related to solubility, structural integrity and biological activity can still exist.”).
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secrets.84 Thus, even small changes in the process of generating a
biologic “could result in a dramatically different final product.”85
The most important aspect of this entire process is maintaining
the activity of the protein.86 If the protein is over-expressed and
purified, but is unable to function properly within a patient’s body
upon injection, the pharmaceutical company has failed.87 Unlike
drugs, which are small molecules that eventually break down over
time, proteins may just not work at all.88 A drop in the activity of
proteins can easily occur because of glitches in the purification
process.89
Researchers must monitor protein purity and activity because
such differences can affect the body in a variety of ways.90 For
example, if a patient’s normal physiological process cannot
produce a functional protein, he absolutely requires a perfect
biologic. Furthermore, protein activity is crucial for dictating the
dosage of the protein.91 For instance, if a brand-name biologic is
twice as active as the generic, twice the amount of the generic
biologic would have to be injected into the patient.92 Notably, the
difference between dosages would suggest that the follow-on
biologic is not a bioequivalent, but a biosimilar.93 Whether the
84

See infra notes 308–10 and accompanying text.
Gitter, supra note 30, at 561.
86
Protein Crystallography, Protein Purification in One Day: Introduction,
http://proteincrystallography.org/protein-purification/introduction.php (last visited Oct.
31, 2009) (stating that almost all proteins lose their activity and crystallization ability
during manipulations).
87
See id. (“[F]or some proteins, even one extra day when they are being kept under
conditions normally used for protein purification could be crucial in respect to their
activity and crystallization ability.”).
88
See Liang, supra note 76, at 369 (explaining the composition of a biologic versus a
drug).
89
See generally PROTEIN PURIFICATION HANDBOOK, supra note 79.
90
See generally id.
91
See ClinicalTrials.gov, A Phase I, Dose-Escalation Study to Assess the Safety and
Biological Activity of Recombinant Human Interleukin-18, http://clinicaltrials.gov/ct2/
show/NCT00500058 (last visited Nov. 10, 2009), as an example of a biologic clinical
trial attempting to identify a safe and effective dosage of the interleukin-18 drug, which is
a protein in humans.
92
See id.
93
See Kelleher, supra note 43, at 254 (“When two chemically-synthesized drugs are
proven bioequivalent, their safety and efficacy can be assumed because two identical
drugs will consistently produce the same reactions.”).
85
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research and design teams can generate an equivalent from the
beginning (over-expression) to the end (purification process)
factors into the importance of trade secrets.94
The FDA has previously relied on the Restatement of the
Uniform Trade Secrets Act in defining property interests.95 Under
the Restatement, “[a] trade secret may consist of any commercially
valuable plan, formula, process, or device that is used for the
making, preparing, compounding, or processing of trade
commodities and that can be said to be the end product of either
innovation or substantial effort.”96 As a result, trade secrets that
pharmaceutical companies keep can and likely will translate into
differences between biosimilars.97
In summary:
[M]anufacturing biologics can pose several
problems, including: (1) the nature of manufacture;
(2) the unlikelihood that a generic manufacturer
could successfully reverse engineer the exact steps
of synthesis used by the brand manufacturer; (3) the
complexity and size of the molecules; (4) the
possibility for serious and unpredictable side effects
with even a small change; and (5) the difficulty of
quality control, for even a meticulous replication of
a biological compound is not identical to the
developed compound it attempts to mimic. Such
drugs are thus termed “biosimilar,” since similarity
to the biological molecule is all that can realistically
be claimed.98

94

Corbitt, supra note 7, at 398.
Andrew Wasson, Taking Biologics for Granted? Takings, Trade Secrets, and Off
Patent Biological Products, 2005 DUKE L. & TECH. REV. 4, 5.
96
21 C.F.R. § 20.61(a) (2009); see also Wasson, supra note 95, at 12 (quoting 21
C.F.R. § 20.61(a)).
97
See Corbitt, supra note 7, at 398.
98
Id. at 378.
95
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D. The Hatch-Waxman Act
1. Overview
Congress passed the Hatch-Waxman Act99 in 1984 to balance
the competing interests of generic pharmaceutical companies and
brand-name pharmaceutical companies.100
To promote
competition with brand-name drug manufacturers, generic
pharmaceutical companies need to gain immediate approval for
selling the follow-on drug.101 Thus, these companies require a
reduced process for drug approval and an accelerated patent
litigation process.102 Meanwhile, brand-name pharmaceutical
companies must preserve their profit margins to be able to afford
research and development of drugs.103
To balance the competing interests of brand-name and generic
pharmaceutical companies, the Hatch-Waxman Act permits the
filing and evaluation of “Abbreviated New Drug Applications”
(“ANDA”s).104 By securing an ANDA, a company is permitted to
generate a generic version of a patented drug.105 The company
must prove that the drug is safe and effective to secure an
ANDA;106 to do this the applicant merely must submit
experimental proof that the brand-name drug and the replicated
generic are equivalent.107
An ANDA certifies one of four possibilities: “1) the drug has
not been patented; 2) the patent has expired; 3) the generic will not
be sold on the market until after the date which the patent will
expire; and 4) the patent is not infringed or is invalid.”108 If the
ANDA is filed under the circumstance that the patent is not
99

See 98 Stat. 1585 (1984) (codified as amended at 21 U.S.C. § 355 and 35 U.S.C. §
271(e) (2006)).
100
Id.
101
Corbitt, supra note 7, at 372.
102
Id.
103
Id.
104
Id.
105
Id.
106
Id.
107
Id.
108
Gerald J. Mossinghoff, Overview of the Hatch-Waxman Act and Its Impact on the
Drug Development Process, 54 FOOD & DRUG L.J. 187, 189 (1999).
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infringed or is invalid, the applicant must give notice to the patent
holder that it has filed an ANDA.109 The applicant notifies the
patent holder under these conditions because filing the ANDA
constitutes literal infringement.110
Further, the ANDA is
processed, but final approval is not granted during the thirty month
stay in order for both parties to litigate the allegation of invalidity
and/or non-infringement.111
The patent-holder has forty-five days to file suit for
infringement in order to obtain the benefit of the thirty month stay
of approval.112 If the patent-holder chooses to file suit, the FDA
will not grant final approval of the ANDA for thirty months,
permitting litigation between the parties.113 The brand-name
pharmaceutical company could win patent term extensions and
market exclusivity provisions,114 while the generic company could
win 180 days of market exclusivity for the generic equivalent of
the drug.115 Thus, while ANDAs give the generic companies the
ability to quickly begin marketing and selling a bioequivalent
product,116 the brand-name companies enjoy the notice
requirement with the possibilities of term extensions and market
exclusivity.117
2. Hatch-Waxman Act Application to Generic Biologics
Congress has tried to apply the Hatch-Waxman Act to
biologics.118 Biologics are complex proteins that are manufactured
within cells (in vivo), not in test tubes (in vitro).119 Currently,
however, some of the smaller biological matter is classified as
109

Id. at 190.
Corbitt, supra note 7, at 373.
111
Id.
112
Id.
113
Id.
114
Id.
115
Id.
116
Id.
117
Id.
118
See H.R. 5629, 110th Cong. (2008); S. 1695, 110th Cong. (2007); H.R. 1956, 110th
Cong. (2007); H.R. 1038, 110th Cong. (2007).
119
Liang, supra note 76, at 369 (describing how biologics production introduces DNA
into a cell line); see also ALBERTS ET AL., supra note 39, at 472 (explaining in vivo and in
vitro procedures).
110
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“drugs” to permit Hatch-Waxman application.120 Two sections of
the Hatch-Waxman Act are utilized for small-molecule drugs:
section 505(j) and section 505(b)(2) of the Food, Drug, and
Cosmetic Act (“FDCA”).121
The more prevalently used section of the Hatch-Waxman Act
for small-molecule drugs is section 505(j) of the FDCA, which
permits an applicant to file an ANDA.122 This section established
the ANDA approval process, allowing cheaper generic forms of
approved innovator drugs to be approved and brought on the
market:123
An ANDA applicant must include in the ANDA
a patent certification described in section
505(j)(2)(a)(vii) of the Act. The certification must
make one of the following statements: (I) no patent
information on the drug product that is the subject
of the ANDA has been submitted to [the] FDA; (II)
that such patent has expired; (III) the date on which
such patent expires; or (IV) that such patent is
invalid or will not be infringed by the manufacture,
use or sale of the drug product for which the ANDA
is submitted. This last certification is known as a
paragraph IV certification.
A notice of the
paragraph IV certification must be provided to each
owner of the patent that is the subject of the
certification and to the holder of the approved NDA
to which the ANDA refers. The submission of an
ANDA for a drug product that is claimed in a patent
is an infringing act if the drug product that is the
subject of the ANDA is intended to be marketed
before the expiration of the patent and, therefore,

120

Liang, supra note 76, at 390.
Federal Food, Drug, and Cosmetic Act § 505(b)(2), 21 U.S.C. § 355(j) (2006).
122
Kelleher, supra note 43, at 249.
123
See U.S. DEP’T OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., CTR. FOR
DRUG EVALUATION & RESEARCH, GUIDANCE FOR INDUSTRY, 180-DAY GENERIC DRUG
EXCLUSIVITY UNDER THE HATCH-WAXMAN AMENDMENTS TO THE FEDERAL FOOD, DRUG,
AND COSMETIC ACT (1998), available at http://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/ucm079342.pdf.
121
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infringement

Section 505(j)(5)(B)(iv) further provides an incentive for
generic manufacturers to file paragraph IV certifications. This
section states that, in certain circumstances,
an ANDA applicant whose ANDA contains a
paragraph IV certification is protected from
competition from subsequent generic versions of the
same drug product for 180 days after either the first
marketing of the first applicant’s drug or a decision
of a court holding the patent that is the subject of
the paragraph IV certification to be invalid or not
infringed.125
Section 505(j) reflects Congress’ intentions to balance
encouraging innovation with the need to provide cheaper
alternatives to the American public.126
The less utilized section of the Hatch-Waxman Act is section
505(b)(2). The FDA has only been able to approve biological
therapies using section 505(b)(2) when these compounds are
classified as drugs, despite being biologics.127
Created in 1984 as part of the Hatch-Waxman
Amendments to the Federal Food, Drug, and
Cosmetic Act, the 505(b)(2) application is intended
to encourage sponsors to develop innovative
medicines using currently available products.
According to Section 505(b)(2) guidelines, an NDA
approval can be obtained for a new drug without
conducting the full complement of safety and
124

Id. at 3–4.
Id. at 4.
126
Follow-on Protein Products: Hearing on Safe and Affordable Biotech Drugs Before
H. Comm. on Oversight and Government Reform, 110th Cong. (2007), available at
http://www.fda.gov/NewsEvents/Testimony/ucm154070.htm (statement of Janet
Woodcock, M.D., Deputy Commissioner and Chief Medical Officer, Food and Drug
Administration).
127
Nathan A. Beaver & Kelly A. Hoffman, Final Word: Omnitrope’s Approval: What
Does it Mean for Other Generics?, BIOPHARM INT’L, Aug. 1, 2006, http://biopharm
international.findpharma.com/biopharm/article/articleDetail.jsp?id=361018.
125

GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE)

2009]

12/30/2009 10:48:32 AM

FIXING A HOLE

345

efficacy trials and without a “right of reference”
from the original applicant. . . . [505(b)(2)] proposes
a limited change to a previously approved product,
but demonstrates the required safety and efficacy of
the change.128
Some examples of generic drugs that the FDA has approved
using this section are recombinant follitropin beta (Follistim®),
recombinant human glucogon (GlucaGen®), and human growth
hormone (Omnitrope®).129 Section 505(b)(2) is essentially a
hybrid between a NDA and an ANDA, as applicants may rely on
the experimentation conducted by a third party, including the
innovative manufacturer, to show the safety of their own
products.130 The applicant need not perform many of the trials
himself if he proves the “relevance and applicability” of any
previous clinical findings.131 Thus, the applicant can evade much
of the cost associated with seeking FDA approval of a new drug.
The FDA is hesitant to approve more complex biological
therapies under section 505(b)(2).132 While the FDA has approved
biologic drugs under section 505(b)(2), such as menotropins,
glucagon, and calcitonin, generally the FDA maintains that followon biologics “present unique and difficult questions that will be
addressed in a timely manner.”133 Therefore, the use of this
pathway within the Hatch-Waxman Act is limited. Use of this
provision would require biological substances to gain approval as
new drugs under the FDCA or the Hatch-Waxman provision, as
approved under the PHSA.134 However, this is unlikely, as
Congress is not considering any legislation that would clarify or
expand FDA authority to regulate and approve generic
128

Kenneth V. Phelps, The 505(b)(2) Alternative—An NDA That Saves Time and
Money, DIA FORUM, Mar. 2005, available at http://www.camargopharma.com/Userfiles/
Docs/camargo-505b2.pdf.
129
See Liang, supra note 76, at 393–97.
130
Kelleher, supra note 43, at 250.
131
Id.
132
Id. at 251.
133
Kenneth D. Growth, Biosimilars Shake Up the Biologics Market, GENETIC
ENGINEERING NEWS, Dec. 1, 2005, at 48, available at http://www.genengnews.com/
articles/chitem.aspx?aid=1159&chid=0; see also Beaver & Hoffman, supra note 127.
134
Beaver & Hoffman, supra note 127.
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biologics.”135 Thus, section 505(b)(2) is not a practical pathway to
pursue to gain generic approval of biological material as the FDA
has expressed discomfort in using this pathway for this exact
reason.136
3. The Uncertain Future of the Hatch-Waxman Act
Since there has not been a uniform approval process for
producing generic biologics under existing United States law,
Congress attempted to enact the Biologics Act of 2007.137 At the
Biosimilars Conference in 2007, Representative Henry Waxman
stated that biotechnology drugs embody the future of medicine, as
there were almost 500 new such drugs in development.138 The
FDA has not regulated the majority of new biologics as new drugs
under the FDCA, but instead under the PHSA.139 Thus, an
applicant would file a biologics application (“BLA”), but not a
NDA.140 A BLA confirms the safety and purity of the drug.141
Companies, however, may not file a BLA for most biosimilars due
to current practice.142 The FDA has only approved the smaller,
simpler biological “drugs” for manufacture through an NDA, such
as insulin and human growth hormone (“HGH”).143 Therefore,
companies may manufacture the drugs generically through an
ANDA.144 It is not clear, however, why few biologically based
drugs are permitted through this process.145 There are also
currently no guidelines to lead manufacturers in filing a NDA or a
BLA application.146
There is still no clear process for approval for generic
biologics. An illustration of how the absence of such guidelines
135

Id.
Id.
137
See Congressman Henry A. Waxman, Remarks at Biosimilars 2007 Conference
(Sept. 24, 2007), available at http://www.biosimilarstoday.com/Waxman.pdf.
138
Id.
139
Kelleher, supra note 43, at 251.
140
Liang, supra note 76, at 392.
141
Id.
142
Id.
143
See id. at 390–97.
144
See id.
145
Id.
146
Liang, supra note 76, at 392.
136
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affects competition is the court decision in Sandoz, Inc. v.
Leavitt.147 Sandoz, Inc. (“Sandoz”) was a generic drug subsidiary
of Novartis, one of the largest multi-national pharmaceutical
companies.148 Sandoz sued Michael Leavitt, the Secretary of
Health and Human Services, and Andrew Von Eschenback, the
acting Commissioner of the FDA, because Sandoz wanted to sell
Omnitrope.149 Omnitrope was going to be a follow-on drug
comparable to Genotropin, a substitute for HGH.150 Low levels of
HGH cause various growth disorders and Genotropin could
alleviate this condition.151 To market and sell Omnitrope, Sandoz
submitted an ANDA to the FDA in 2003 and stated that this
follow-on drug was safe and identical to the pioneer drug,
Genotropin.152 The FDA deferred its decision and did not act
within 180 days; therefore, Sandoz filed suit.153 At the time, like
today, there was still no clear process for approval:
It is true that today the FDA regulates most
biopharmaceuticals under the Public Health Service
Act, which as previously discussed, is not part of
the Hatch-Waxman regime. But the Public Health
Service Act has for many years contained a
provision stating that nothing in that Act shall affect
the FDA’s jurisdiction under the FDCA, and it is
clear
that
FDA
could
regulate
all
biopharmaceuticals under the FDCA, as it had
chosen to do for insulin and human growth
hormone.154
The Sandoz court sidestepped the issue of defining a process
for approving the production of generic biologics.155 It directed
147

427 F. Supp. 2d 29 (D.D.C. 2006).
Id. at 31–32.
149
Id. at 32.
150
Id.
151
Id. at 31.
152
Id. at 32.
153
Id.
154
The Law of Biologic Medicine: Hearing Before the S. Comm. on the Judiciary,
108th Cong. (2004) (statement of William Schultz, Partner at Zuckerman Spaeder, LLP),
available at http://judiciary.senate.gov/hearings/testimony.cfm?id=1239&wit_id=3627.
155
See Sandoz, 427 F. Supp. 2d at 41.
148
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the FDA to immediately decide whether to approve the license of
Omnitrope.156 The FDA then approved Omnitrope as a “follow-on
protein product” but not as a biologic.157 The FDA further
expressed that the approval of Omnitrope did not carve out a
guaranteed pathway to gain approval of other biosimilars.158 Some
have suggested that Congress should take legislative action in
response to the district court decision in Sandoz.159
In addition, it may be necessary to create legislation to clarify
the FDA’s role and responsibilities in the approval process.160
There has been an increased need to have a process promptly put in
place because the first generation of biologic therapies will expire
in 2015.161 The public need for competition will not be met if
there is no expedited pathway for approval of generic biologics.162
Importantly, applicants attempting to gain approval for the
manufacture of generic biologics must also submit: 1) analytical
studies demonstrating biosimilarity, 2) animal studies, and 3) a
minimum of one clinical study that demonstrates safety, purity,
and potency.163 Since analytical studies, animal studies, and
clinical studies take years to perform, competition between
innovative and follow-on biologics could be compromised.
Additionally, Representative Waxman has concerns regarding
the length of brand-name exclusivity. Representative Waxman
argues that a reasonable term of exclusivity is “not one that is so
long that it would rob the American people of the cost-saving
appropriate generic competition brings,”164 and that such a term
should be less than ten years.165 While it is important that generic
biologics must become available to drive costs down and facilitate
competition, incentives for brand-name pharmaceuticals must

156
157
158
159
160
161
162
163
164
165

Id.
Kelleher, supra note 43, at 251.
Id. at 251–52.
Id. at 252.
Corbitt, supra note 7, at 381.
Id.
See Kelleher, supra note 43, at 252.
See Liang, supra note 76, at 384–85.
See Waxman, supra note 137.
See id.
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remain high.166 Those against the Waxman Bill believe that if it
becomes easier for generic biologics to compete with brand-name
biologics and/or the term of exclusivity is significantly
abbreviated, innovative pharmaceutical companies will lose
incentive to continue current research and development.167
Despite Representative Waxman’s optimism for the future of
generic biologics, many economists challenge the idea that access
to follow-on biologics will decrease prices for consumers.168
Economists estimate that the cost of producing and experimenting
upon generic biologics will be a great deal higher than with smallmolecule drugs.169 “The cost associated with getting a biogeneric
to market could be tens of millions of dollars, as compared to a
couple of million dollars for traditional generics.”170 Additionally,
biologics have more specific, targeted activities compared to small
molecule drugs.171 This translates to smaller markets that are
interested in investing in such therapies.172 Thus, one can easily
argue that very few companies are likely to prosper in generating
follow-on biologics.173
E. What Americans Can Learn from the EU
On the other hand, the European Union (“EU”) has a system
that permits generic biologic approval and has saved several billion
dollars from the market entry of only a few products.174 The EU
established a regulatory approval process for biosimilar medicines
166

Donald Zuhn, BIO CEO Makes Case for 12-Year Data Exclusivity Period, PATENT
DOCS, Aug. 16, 2009, http://www.patentdocs.org/2009/08/bio-ceo-makes-case-for12year-data-exclusivity-period.html.
167
See id.
168
See Suzanne M. Sensabaugh, Biological Generics: A Business Case, 4 J. GENERIC
MED. 186, 188–89 (2007).
169
See id. at 189.
170
Kelleher, supra note 43, at 253.
171
See Liang, supra note 76, at 369.
172
See generally U.S. CONG. BUDGET OFFICE, HOW INCREASED COMPETITION FROM
GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY
13–35 (1998), available at http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf.
173
See generally id.
174
Kathleen Jaeger, GPhA President and CEO, GPhA Speech at Windhover FDA/CMS
Summit (Dec. 5, 2006), available at http://www.gphaonline.org/resources/2006/12/04/
gpha-speech-windhover-fdacms-summit.

GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE)

350

12/30/2009 10:48:32 AM

FORDHAM INTELL. PROP. MEDIA & ENT. L.J.

[Vol. 20:327

in Europe in 2006, when the European Commission approved the
first biosimilar medicines.175
All biotechnology medicines, including
biosimilar biotechnology-derived medicines, are or
will be assessed by the European Medicines Agency
in London (EMEA), which constitutes the scientific
body of the European Commission responsible for
the evaluation of medicines. They are approved by
the European Commission based on the positive
scientific opinion issued by the EMEA.
When the EMEA assesses data for a biosimilar
medicine, the scientific principles for ensuring
product quality, safety and efficacy are identical to
those applied to the originator/brand reference
medicine with which comparability is demonstrated.
In addition to the quality data required for all
biotechnology products, the companies involved in
the developing biosimilar medicines must
additionally submit “comparability data.” Indeed,
manufacturers must characterize, in parallel, both
their biosimilar product and the originator reference
product. They must demonstrate, with a high
degree of certainty, that the quality of the biosimilar
medicine is comparable to the originator/reference
medicinal product. A comparability programme is
clearly defined and agreed upon in advance with the
EMEA, who defines the set of non-clinical and
clinical data that are necessary to sufficiently
demonstrate biosimilarity. The extent of this data
varies according to the type and complexity of the
medicine involved. Each individual biosimilar
medicine is assessed on a case-by-case basis.176
In addition, the EU states that patients can be assured of safety
because of two systems: regulations require that the European
175

Liang, supra note 76, at 399–400.
European Generic Medicines Association, FAQ on Biosimilar Medicines,
http://www.egagenerics.com/doc/FAQ_biosimilars.pdf (last visited Aug. 27, 2009).
176
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pharmaceutical companies monitor the use and effects of their
medicines and provide that a Risk Management Plan is required for
each new biosimilar medicine.177
The EU notes that “[t]he price differential between a reference
product and a biosimilar medicine will depend on the relative
development costs.”178 While the EU is optimistic about the
relative savings courtesy of biosimilars, development costs may
compromise savings.179
F. The Public Health Service Act
1. Biologics in the Eyes of the Public Health Service Act
A biological product, as defined by the PHSA, is “a virus,
therapeutic serum, toxin, antitoxin, vaccine, blood, blood
component or derivative, allergenic product, or analogous product,
or arsphenamine or derivative of arsphenamine (or any other
trivalent organic arsenic compound), applicable to the prevention,
treatment, or cure of a disease or condition of human beings.”180
Some examples of biologics include some vaccines, and
monoclonal antibodies, which can aid in the treatment of cancer,
anemia, hepatitis, and multiple sclerosis.181
Biologic product sales are continually increasing, with
American product sales jumping from $32.8 billion to $56 billion
from 2005 to 2006.182 Global sales are expected to reach $105
billion by 2010.183 In the past ten years, the patents of more than a
dozen high-profit biologics have expired, creating $11.5 billion in
combined annual sales of off-patent biologics.184

177

Id.
Id.
179
See id.
180
42 U.S.C. § 262(i) (2006).
181
Kelleher, supra note 43, at 247.
182
Gregory Roumeliotis, FDA Under Pressure to ‘Open the Floodgates’ for
Biogenerics, IN-PHARMA TECHNOLOGIST.COM, Aug. 17, 2006, http://www.inpharmatechnologist.com/news/ng.asp?n=69925-fda-biogenerics-insulin-hgh-omnitrope.
183
Kelleher, supra note 43, at 247.
184
Meredith Wadman, Copycats Gear Up to Dog Biotech Brands, NATURE, Oct. 5,
2006, http://www.nature.com/nature/journal/v443/n7111/full/443496a.html.
178
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With a few exceptions, generic biologics have not been able to
enter the market due to the current regulatory scheme.185 One
method of approving generic biologics is by enlarging the HatchWaxman Act.186 However, because biological products are highly
complex and vary vastly from generic drugs, a new regulatory
scheme would need to be put in place for generic biologics to
compete.187
2. Comparison to the Food, Drug, and Cosmetic Act
The regulation of biological products is unique from smallmolecule drugs. Most biologics are not regulated as drugs under
the FDCA but are instead licensed under section 351 of the PHSA
and then evaluated by the Center of Biologics Evaluation and
Research (“CBER”).188 Under the PHSA, each biologic must
secure a license, which validates the product as safe and pure.189
The PHSA does not contain a provision for follow-on biologic
approval.190
Whereas the PHSA ostensibly applies to most or all biologics,
the FDCA, on the other hand, has decided to regulate a small
number of biologics, such as insulin and HGH.191 Despite
providing no clear explanation as to why only these biologics are
regulated by the FDCA, such regulation falls under the FDCA.192
The FDCA’s definition of a “drug” includes “articles intended for
use in the diagnosis, cure, mitigation, treatment, or prevention of
disease in man.”193 Thus, this language suggests that the FDCA’s
regulation encompasses biological materials as well as drugs.194

185
186
187
188
189
190
191
192
193
194

Liang, supra note 76, at 409.
Supra note 2.
Wasson, supra note 95, at 3.
Id. at 4.
Id.
Id.
Kelleher, supra note 43, at 249.
Wasson, supra note 95, at 9.
21 U.S.C. § 321(g)(1)(B) (2006).
Id.
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G. A Tale of Two Bills: The Next Chapter
President Obama’s 2010 budget proposal creates an
abbreviated pathway for follow-on biologics.195 The 111th
Congress will consider two competing pieces of legislation: House
Bill 1427 (the Waxman Bill)196 and House Bill 1548 (the Eshoo
Bill).197 The Waxman Bill and the Eshoo Bill would amend the
PHSA to add a subsection permitting follow-on biologics to enter
the market.198 The two issues that are at the heart of these bills are:
1) the term of exclusivity of the pioneer company, and 2) the
evidence required to show that the generic biologic is biosimilar to
the pioneer biologic.199 Congress considered similar legislation in
past years, but the current presidential and bipartisan support will
likely lead to enactment of a generic approval.200 While the
Waxman Bill favors quicker public access to generic biologics,201
the Eshoo Bill encourages more testing before approving the
biologic.202
Generic manufacturers support the Waxman Bill, while
innovative manufacturers favor the Eshoo Bill.203 Both the
Waxman Bill and the Eshoo Bill will permit the FDA to license
biologics deemed “biosimilar.”204 The Waxman Bill defines
“biosimilar” by stating that “no clinically meaningful differences
between the biological product [follow-on biologic] and the
reference product [innovative biologic] would be expected in terms
of the safety, purity, and potency if treatment were to be initiated

195

See Barbara Carter, Congress Answers the Call to Permit Generic Versions of
Biologic Drugs, SUNSTEIN INTELL. PROP. UPDATE, Mar. 2009, http://www.bromsun.com/
publications-news/news-letters/2009/03/200903biologics.html.
196
H.R. 1427, 111th Cong. (2009).
197
H.R. 1548, 111th Cong. (2009).
198
Rep. Eshoo Proposes Draft Biogenerics Bill, FDA Law Blog, http://www.fdalaw
blog.net/fda_law_blog_hyman_phelps/2008/02/a-peek-inside-p.html (Feb. 18, 2008,
07:26 EST).
199
H.R. 1548, 111th Cong. (2009); see also FDA Law Blog, supra note 198.
200
Ramon Tabtiang et al., Congress Considers Competing Biosimilar Legislation, FISH
NEWS, http://fr.com/news/articledetail.cfm?articeid=939.
201
Carter, supra note 195.
202
Id.
203
Tabtiang et al., supra note 200.
204
Id.
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with the biological product instead of the reference product.”205
Both bills require generic biologic applicants to submit data
indicating that any biogeneric has highly similar molecular
structure to the reference product.206
A key assertion in the Eshoo Bill is that a generic biologic is
not identical to the innovative biologic.207 The Eshoo Bill states
that a generic biologic can never be substituted for an innovative,
pioneer biologic.208
Additionally, the Eshoo Bill requires
analytical and animal studies to show that the follow-on biologic is
highly similar to the innovative biologic.209 This bill will permit
the FDA to waive these tests, but only after requesting and
considering public comments regarding the balancing of price
competition and safety.210
The Waxman Bill, on the other hand, proposes comparatively
lenient standards for determining equivalence between pioneer and
follow-on biologics.211 This bill proposes that a follow-on biologic
only have “highly similar molecular structural features” or have
“interchangeability with” the pioneer drug.212 Generic drug
companies can easily satisfy this requirement, as these companies
may use the clinical studies and efficacy tests initially performed
by the pioneer company.213 Thus, this bill does not require the
pharmaceutical company to perform further testing. 214
The Eshoo Bill and the Waxman Bill also differ with respect to
exclusivity. The Eshoo Bill allows for twelve years of data
exclusivity and provides up to two more years for a new use
approved for the pioneer biologics.215 However, the Waxman Bill
suggests a short exclusivity period of five and a half years, and

205
206
207
208
209
210
211
212
213
214
215

H.R. 1427, 111th Cong. § 3(k)(1) (2009).
Tabtiang et al., supra note 200.
H.R. 1548, 111th Cong. (2009).
Id.
Id.
Id.
Carter, supra note 195.
Id.
Id.
Id.
H.R. 1548, 111th Cong. (2009).
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three more years of data exclusivity for new uses and formulations
of the innovative biologic.216
II. CARRY THAT WEIGHT: HOW PENDING LEGISLATION ALTERS
THE CURRENT MODEL
There are great concerns about how amendments to the HatchWaxman Act, in the form of the Waxman and Eshoo Bills, may
change the face of patent law. A patent requires the inventor to
release information that would allow a person having ordinary skill
in the art to recreate the invention completely.217 However, it is
inherent in the definition of a “biologic” that such molecules are
much more difficult to recreate than small molecule drugs.218
Biologics, which researchers and companies grow and harvest in
vivo, present many hurdles that make them difficult to recreate in
the form of generics.219 Because it is so difficult to recreate
biologics, the patent requirement of enablement220 is trickier to
satisfy and makes it more difficult to generate generic biologics.221
Despite this strain on the patent system, there is an enormous and
still growing need for generic biologics.222 The mounting
necessity for generic biologics puts a strain on two opposing needs:
1) the need for generic biologics to slash costs,223 and 2) the
requirement that all biologic medication being sold is
bioequivalent to the innovative biologic and is safe to use.224

216

H.R. 1427, 111th Cong. (2009).
Corbitt, supra note 7, at 397.
218
See id. at 377.
219
Id. at 378.
220
35 U.S.C. § 112 (2006) (stating that the specification must describe how to make
and use the invention to one skilled in the art); see also United States Patent and
Trademark Office, 2164 The Enablement Requirement [R-2]—2100 Patentability,
http://www.uspto.gov/web/offices/pac/mpep/documents/2100_2164.htm (last visited Oct.
16, 2009).
221
See Corbitt, supra note 7, at 367–68.
222
Id. at 369.
223
Id.
224
Id. at 372.
217
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A. The Intersection Between Patent Law and Biologics
Because of the chemical differences between simple smallmolecule drugs and complex biological compounds, several
problems arise when trying to apply the current Hatch-Waxman
provisions to biological compounds.225 Biologic compounds are
larger and more complex than small-molecule drugs, requiring a
more sophisticated and regulated methodology of production.226
Because of the intricacies in producing sensitive biologics, small
changes in production could have severe and far-reaching
consequences in a patient’s health.227
Besides the health concerns associated with taking generic
forms of biologic compounds, there are general concerns about the
impact of biologic legislation on United States patent law.228
“First, if it is impossible to synthesize an identical compound the
effect could be to preclude patentability on the grounds of
‘enablement.’”229
The patent-holders, the brand-name
pharmaceutical companies, would walk a thin line if required to
argue the conflicting ideas that their product is enabled and yet it is
impossible to replicate due to the nature of production.230 Second,
patentability is questioned because many biologics are compounds
already produced, in vivo, in every healthy human being.231 Thus,
while the process of generating large quantities of any biologic can
be novel, the biological compound may not meet the patentability
requirement of novelty.232 The legislators must consider these
problems before they assume that the parameters set in place by
the Hatch-Waxman Act, written for competition of small-molecule
drugs,233 will directly apply to biologics.
In addition to enablement for patent eligibility, one must also
show novelty. To be novel, an invention must be new, unknown to
225
226
227
228
229
230
231
232
233

Id. at 397.
See supra notes 41–59.
Corbitt, supra note 7, at 366–67.
Id. at 367.
Id.
Id. at 367–68.
Id. at 368.
Id.
Id.
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the public, and not published (or described in a pending U.S. patent
application) anywhere.234 Diamond v. Chakrabarty, a landmark
Supreme Court case, allowed biotechnology innovation to fall
within the scope of statutorily patentable inventions.235 The Court
stated that a living organism can be patentable as long as it was not
naturally-occurring.236 Thus, discoverable matter is not patentable,
while inventions are patentable.237 This principle extends to the
biological therapies that would be encompassed by the Biologics
Act, if the legislation passes. For example, a purified protein is
patentable because there is a difference between pure and impure
materials.238 Thus, a patentable innovation can be the actual
purification process, despite the fact that the product itself is
naturally-occurring.
B. Why Push for Generic Biologics?
As discussed earlier,239 Americans are deeply concerned about
the cost of drugs,240 and they have therefore embraced generic
alternatives. Generic alternatives have also made a lasting
impression on the pharmaceutical industry.241 Ten years after the
Hatch-Waxman Act was passed in 1994, Americans saved between
$8 and $10 billion in drug stores by purchasing generic drugs
instead of brand-name drugs.242 Americans have shown the
pharmaceutical companies that they want to decide between a
brand-name form of a small-molecule drug and the generic
equivalent, and that they want to save money.243 This financial
need for cheaper drugs translates into the public wanting and
needing competition between brand-name and generic biologics.244
234

35 U.S.C. § 102 (2006).
Diamond v. Chakrabarty, 447 U.S. 303, 316 (1980) (“A rule that unanticipated
inventions are without protection would conflict with the core concept of the patent law
that anticipation undermines patentability.”).
236
See id at 317.
237
Id. at 309.
238
In re Bergstrom, 427 F.2d 1394, 1402 (C.C.P.A. 1970).
239
See supra notes 1–8 and accompanying text.
240
See supra note 1 and accompanying text.
241
See U.S. CONG. BUDGET OFFICE, supra note 172.
242
Id. at ix.
243
See id.
244
Id. at x.
235
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By facilitating price competition through passing new legislation,
for example via the Eshoo Bill or Waxman Bill, more follow-on
biologics would be available to patients.245
Generic drugs, though, have hampered the innovative
pharmaceutical industry’s ability to recover investment costs.246
Investment in research and development has increased from 14.7%
to 19.4%, while sales rose from $17 billion to $57 billion between
1983 and 1995.247 These ascending numbers, however, hardly
account for innovative pharmaceutical companies branching out in
research and development more rapidly, resulting from generic
pharmaceutical companies pushing to sell on the market.248
Follow-on drugs, also called generic small-molecule drugs, have
surely cut into brand-name drug revenue.249
C. No Consensus on Exclusivity
Each of the two pending bills appeal to either the innovative
pharmaceutical industry or the generic pharmaceutical industry.
Innovative and generic pharmaceutical companies have agreed that
there is a need for follow-on biologics; however, they disagree
about the exclusivity period for brand-name drugs.250 Generic
companies favor shorter periods of exclusivity, approximately
seven years, while innovative pharmaceutical companies support
bills providing twelve to fourteen years of exclusivity.251
Five congressional bills introduced in 2007 and 2008 began a
thoughtful discussion regarding generic biologics, but they
ultimately did not pass.252 These bills would have amended
245

Id.
Id. at xiii.
247
Id. at xv.
248
See id.
249
Associated Press, Brand Name Drugs Going Generic, NBC ACTION NEWS.COM,
Dec. 10, 2008, http://www.nbcactionnews.com/mostpopular/story/Brand-Name-DrugsGoing-Generic/j5hxwTekPkSZG-NWWQ31MA.cspx. In the United States, generic
prescription drugs cost approximately 1/3 less than brand name drugs. Id.
250
See Pollack, supra note 1.
251
Donald Zuhn, Top Stories of 2008: #9 to #6, PATENT DOCS, Jan. 4, 2009,
http://www.patentdocs.org/2009/01/top-stories-of-2008-9-to-6.html.
252
H.R. 5629, 110th Cong. (2008); S. 1695, 110th Cong. (2007); S. 1505, 110th Cong.
(2007); H.R. 1956, 110th Cong. (2007); H.R. 1038, 110th Cong. (2007).
246
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section 351 of the PHSA to establish a route for approval of an
abbreviated biological product application for products that contain
the same or similar active ingredients as previously licensed
biological products.253
The Access to Life-Saving Medicine Act, House Bill 1038,254
was introduced February 14, 2007, by Representative Henry
Waxman and stipulated that the biosimilar and reference must have
the same mechanism of action for the same condition of use,255 but
did not mention the provisions for data and market exclusivity.256
The Patent Protection and Innovative Biologic Medicines Act,
House Bill 1956, was introduced April 19, 2007, by Representative
Jay Inslee, and stated that biosimilar and reference material must
merely show comparative results in health-related assays for the
same dosage.257 House Bill 1956 took a bold move and provided
twelve years of data exclusivity and just two years of market
exclusivity.258 The Biologics Price Competition Innovation Act,
Senate Bill 1695, was introduced on June 26, 2007, as a bipartisan
effort guided by Senators Kennedy and Hatch, and suggested that
the biosimilar and reference must have the identical route of
administration, dosage form, and strength, as well as utilize the
same mechanism of action for the same condition of use.259 The
Biologics Price Competition Innovation Act, Senate Bill 1695,
additionally called for four years of data exclusivity and eight
years of market exclusivity.260 House Bill 5629, the Pathway for
Biosimilars Act, would have provided four years of data
exclusivity and eight years of market exclusivity. None of these
bills, however, were passed in the 110th Congress.261

253
254
255
256
257
258
259
260
261

Id.
H.R. 1038, 110th Cong. (2007).
Id. § 3(k)(1)(C).
See Zuhn, supra note 251.
H.R. 1956, 110th Cong. § 2(k)(5)(B) (2007).
See Zuhn, supra note 251.
S. 1695, 110th Cong. § 2(k)(2)(A)(i) (2007).
Id.; see Zuhn, supra note 251.
See supra text accompanying note 252.
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A Teva-funded study262 suggested that an exclusivity period of
seven years would be “sufficient for maintaining strong incentives
to innovate while fostering a competitive marketplace.”263 Teva
also questioned the need for exclusivity provisions that would add
an additional seven to twelve years of protection.264 However,
innovative companies have been supportive of bills that provide
twelve to fourteen years of exclusivity.265 Thus, these studies
illustrate the disconnect between innovative and generic companies
regarding exclusivity periods.
D. A Professor’s View
Dr. Richard G. Frank, a leader in the field of health
economics,266 has expressed that “the Hatch-Waxman framework
is not sufficient to cover both relatively simple biopharmaceuticals
and very large and complex molecules—a new regulatory
framework is needed.”267 While he acknowledges that the loss of
patent protection increases the urgency for regulatory policy
promoting price competition and preserving the safety and efficacy
standards,268 he states that the FDA should receive a “great deal of
discretion” in making multifaceted, situation-specific judgments.269
Thus, “the conflicting goals of bolstering price competition in
biopharmaceutical markets and preserving for a nuanced policy
that must be based on the best science and key features of the
current economics of biopharmaceutical markets—not on the
impassioned claims of the interested parties,”270 create a difficult
set of parameters that requires situation-specific balancing.

262

Teva is a leading company that specializes in follow-on drugs. Posting of Elysa
Brooke Goldberg, Ph.D. to IPLJ Law Blog, http://iplj.net/blog/archives/381 (Apr. 14,
2009).
263
ALEX M. BRILL, PROPER DURATION OF DATA EXCLUSIVITY FOR GENERIC BIOLOGICS 3
(2008), available at http://www.tevadc.com/Brill_Exclusivity_in_Biogenerics.pdf.
264
See generally id.
265
See id. at 6 (discussing Eshoo Bill).
266
Richard G. Frank, Ph.D., Regulation of Follow-On Biologics, 357 NEW ENG. J. MED.
841, 843 (2007), available at http://content.nejm.org/cgi/content/short/357/9/841.
267
Id.
268
Id.
269
Id.
270
Id.

GOLDBERG_NOTE_123009_FINAL (DO NOT DELETE)

2009]

FIXING A HOLE

12/30/2009 10:48:32 AM

361

Dr. Frank interestingly advocates giving the FDA the
discretion to permit generic biologics, instead of problematically
simplifying the approval process via the Hatch-Waxman Act.271
Dr. Frank hypothesizes that if the FDA were to require clinical
studies of generic biologics, then the health of the community
would be a top priority.272 In contrast, he believes that if the
bioequivalence of the complex protein structures were the main
deciding factor alone, the activity of the protein would not be
considered.273 In this way, clinical trials would examine how
effective the follow-on biologic is and be able to compare the
biologic’s strength to the original brand-name biologic. 274
E. Comparing a Patient’s and a Doctor’s View
Thus far, the analysis of this paper addresses if the generics
will be permitted to compete with brand-name pharmaceutical
biologics using today’s legislation.
Another question to
complicate the story is: will doctors prescribe the potential
biosimilar in place of the innovative biologic? Doctors who do not
feel comfortable substituting the generic for the brand-name
biologic could disarm the entrance of biosimilars into the
market.275
Data strongly suggests that both doctors and patients harbor
brand loyalties.276 Many studies analyze patients’ choice to
purchase brand-name pharmaceuticals instead of generic
equivalents.277 One theory is that patients believe generic drugs,

271

Id.
Id.
273
See id.
274
Corbitt, supra note 7, at 388.
275
See GOV’T ACCOUNTABILITY OFFICE, PRESCRIPTION DRUGS: IMPROVEMENT NEEDED
IN FDA’S OVERSIGHT OF DIRECT-TO-CONSUMER ADVERTISING 1–4 (2006), available at
http://www.gao.gov/new.items/d0754.pdf (noting the increase in Direct-to-Consumer
(“DTC”) advertising since 1997 and the implications of this trend for medical
professionals).
276
William H. Shrank, Emily R. Cox, Michael A. Fischer, Jyotsna Mehta & Niteesh K.
Chaudhry, Patients’ Perceptions of Generic Medications, 28 HEALTH AFFAIRS 546, 546
(2009) (reporting results from a study sample regarding patients’ perceptions about
generic drug substitutions).
277
Id.
272
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priced lower than brand-name drugs, are of inferior quality.278 A
telling study performed in 2000 found that “[t]he percentage of
respondents who perceived that generic prescription drugs were
riskier than brand name products varied from 14.2% to 53.8%,
depending on the medical condition being treated.”279 In 2005,
another study found that “37% of patients expressed general
skepticism towards generic drugs because of their lower price.”280
Therefore, many patients ultimately decide against the benefit of
savings offered by generic drugs and instead pay higher prices for
brand-name drugs.281
When faced with the decision to prescribe generics over namebrand pharmaceuticals, physicians conduct themselves similarly to
patients.282 One theory is that physicians tend to be risk-averse and
would prefer not creating variability in patient treatment.283
Physicians have long been criticized as being “creatures of
habit.”284 Such character traits make it difficult to prescribe
generic drugs. However, such caution is well founded. Organic
chemistry has shown that “polymorphism” frequently occurs when
generating drugs.285 Polymorphism is the ability of drugs to exist
in many different types of crystalline phases, all having different
reactivity.286 FDA scientists know that such a cocktail of different
crystalline phases can affect drug stability and drug activity.287
278

Rebecca Ruiz, What You Should Know About Generic Drugs, FORBES, July 27,
2009,
http://www.forbes.com/2009/07/27/generic-drugs-prescriptions-lifestyle-healthdrugs.html.
279
Julie M. Ganther & David H. Kreling, Consumer Perceptions of Risk and Required
Cost Savings for Generic Prescription Drugs, 40 J. AM. PHARM. ASS’N 378, 378 (2000).
280
W. Himmel et al., What Do Primary Care Patients Think About Generic Drugs?, 43
INT’L J. CLINICAL PHARMACOLOGY & THERAPEUTICS 472, 472 (2005).
281
Id.
282
See id. at 477 (“[P]atients as well as physicians do not have the incentive to invest in
low-cost treatment as long as insurance companies pay the costs of prescription,
regardless of their generic or brand-name status.”).
283
F.M. Scherer, Pricing, Profits, and Technological Progress in the Pharmaceutical
Industry, 7 J. ECON. PERSP. 97, 101 (1993).
284
Id.
285
Scientific Considerations of Polymorphism in Pharmaceutical Solids: Abbreviated
New Drug Applications, http://www.fda.gov/ohrms/dockets/ac/02/briefing/3900B1_04_
Polymorphism.htm (last visited Aug. 30, 2009).
286
Id.
287
Id.
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Thus, physicians have good reason to question the ability of
generic drugs to perform comparably to brand-name
pharmaceuticals.
While in theory an active ingredient has the same function and
potency regardless of being brand-name or generic, it is ultimately
the patient that needs to determine if the small molecule is acting
identically. Many patients have noted that they can identify
differences in the potency of brand-name versus generic drugs.288
Because patients question the quality of generic drugs and
physicians err on the side of caution, more brand-name drugs are
routinely prescribed instead of an identical authorized generic to
avoid potential tort liability.289 The fact that generics are poorly
regarded in a percentage of the medical field and in society raises
the question of whether doctors would substitute for and patients
would request follow-on biologics for brand-name biologics.290
On behalf of the innovative brand-name pharmaceutical
companies, the Biotechnology Industry Organization (BIO) is
concerned about doctors being stripped of choice.291 The Waxman
Bill will permit biosimilars to be substituted for the innovative
biologic without the intervention of the prescribing doctor.292 The
generic biologic may be permitted as a substitute without the
doctor’s approval, which could ultimately limit the doctor’s control
and treatment of the patient.

288

See Road Back Foundation, Are Generic Drugs as Effective as Brand Name?—Not
Always!,
http://www.roadback.org/index.cfm/fuseaction/education.display/display_id/
120.html (last visited Aug. 30, 2009).
289
Thomas Chen, Authorized Generics: A Prescription for Hatch-Waxman Reform, 93
VA. L. REV. 459, 477 (2007).
290
Id.
291
See BIO, supra note 24.
292
Jonathan Sheffi, What Are Follow-On Biologics? Will They Really Save Us Billions
of Dollars?, The Soul of Biotech (June 29, 2009), http://www.thesoulofbiotech
.com/2009/06/29/what-are-follow-on-biologics-will-they-really-save-us-billions-ofdollars/.
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F. Brand-Name Perspective: Impossibility of Duplication and the
Question of Patentability
Although patent protection is available for biologics in many
circumstances, there may be a limited scope of protection.293 The
patent system further regulates competition in the biologics
market, as there may be restrictions on the availability of
proprietary rights in biological substances.294 The 110th Congress
reviewed legislation295 that would permit an expedited marketing
approval pathway.296 The Access to Life-Saving Medicine Act,
House Bill 1038 and Senate Bill 623, would have permitted the
Secretary of Health and Human Services to monitor what studies
Comparable
were necessary to establish comparability.297
biologics would be necessary to maintain the same chemical
reaction, the same mechanism of performing this reaction, as well
as the same dosage form, strength, etc.298 While the identical
chemical reaction and mechanism for reaction would be relatively
easy to prove, the same dosage form and strength could be very
tricky to establish.299 If all of these parameters were to be met,
then the generic form of the brand-name biologic would be deemed
“interchangeable.”300 An interchangeable product would be
required to produce the same clinical results as the brand-name
innovative drug.301
There is a formidable lobby, lead by the Intellectual Property
Owners Association, against approval of follow-on biologics,
which strongly asserts that it is impossible to replicate a brandname pharmaceutical’s biological innovations exactly, due to

293

WENDY H. SCHACHT & JOHN R. THOMAS, FOLLOW-ON BIOLOGICS: INTELLECTUAL
PROPERTY AND INNOVATION ISSUES 2 (2008), available at https://www.policyarchive.org/
bitstream/handle/10207/3161/RL33901_20070305.pdf.
294
Id.
295
See supra notes 252–61 and accompanying text.
296
See supra Part III.C.
297
S. 623, 110th Cong. (2007); H.R. 1038, 110th Cong. (2007).
298
S. 623, 110th Cong. (2007); H.R. 1038, 110th Cong. (2007).
299
See supra note 93.
300
See supra note 93.
301
See supra note 93.
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technological limitations.302 The crux of this argument lies in
health and safety concerns, and proponents of this view advocate
against an accelerated approval process for follow-on biologics.303
These pharmaceutical companies assert that an end product is
unpredictable, even with guidance through patent disclosures,
including deposited biological samples.304
This argument
stipulates that since it is impossible to recreate the innovative
biologic perfectly, patent protection should not apply.305
While the safety and health of patients is a strong aspect of this
argument, considering only safety and health undercuts the
patentability of the biologic. Enablement is a fundamental step in
securing patentability.306 If it is impossible to replicate the
patented invention, then there is a prima facie case against
patenting the invention due to non-enablement.307 Using the
inability to fulfill the enablement requirement as an argument
weakens incentives to patent inventions and is unfair. If brandname pharmaceuticals were unable to be patented, companies
would instead use the power of trade secrets to insulate them from
competition.308 Protecting brand-name pharmaceuticals through
trade secrets would drive down the amount of information
available to any pharmaceutical company regarding any type of
technique.309 Consequently, it would be more unlikely that

302
Letter from Herbert C. Wamsley, Executive Director, Intellectual Property Owners
Association, to Anna Eshoo, U.S. H. Rep. (July 17, 2009), available at
http://www.ipo.org/AM/Template.cfm?Section=Board_Resolutions_and_Position_State
ments&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=23296 (memorializing
the IPO’s support for House Bill 1548).
303
Donald Zuhn, IPO Passes Resolution on Biosimilars, PATENT DOCS, Sept. 23, 2008
http://www.patentdocs.org/2008/09/follow-on-biolo.html.
304
Corbitt, supra note 7, at 397.
305
See Stephen B. Judlowe & Brian P. Murphy, IP VALUE 2005, Proposed Legislation
for Follow-On Biologic Pharmaceuticals in the US, http://www.buildingipvalue.com/
05_NA/135_138.htm.
306
35 U.S.C. § 112 (2006). For a description of the enablement requirement, see
United States Patent and Trademark Office, The Enablement Requirement,
http://www.uspto.gov/web/offices/pac/mpep/documents/2100_2164.htm (last visited on
Oct. 14, 2009) [hereinafter The Enablement Requirement].
307
See The Enablement Requirement, supra note 306.
308
Corbitt, supra note 7, at 398.
309
See id.
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competitors would be able to manufacture follow-on biologics.310
Additionally, reverse-engineering would be nearly impossible, so
trade secrets would be a workable way to protect such intellectual
property. If inventions and innovations were protected by trade
secret and not patent law, generic equivalents would be impossible
to generate unless the secrets, for example, were sold.
A major flaw with not extending patentability to innovations
that are very difficult to reproduce is that the innovators no longer
have the protection of a patent. Losing the availability of patent
rights could very likely be a large disincentive to continue funding
pharmaceutical companies and their research and development
efforts. The rights of patents extend from literal infringement
through the doctrine of equivalence (“DOE”).311 The DOE is only
available to patented products, not to those covered via trade secret
because patented innovations are extended protections that trade
secrets are not.312 The DOE allows a court to hold a party liable
for patent infringement for an equivalent to the claimed
invention.313 Courts may use the DOE to stop companies from
avoiding infringing patents by making insubstantial changes to the
innovation.314 Without the DOE, the value of patents “would be
greatly diminished.”315

310

Id. (“If enablement is itself impossible, then trade secret protection might be more
advisable than patent protection, as reverse engineering such a complicated process is
highly improbable.”).
311
See ROBERT P. MERGES, PETER S. MENELL & MARK A. LEMLEY, INTELLECTUAL
PROPERTY IN THE NEW TECHNOLOGICAL AGE 263–64 (4th ed. 2006) (describing how the
doctrine of equivalents expands on patent protection against literal infringement).
312
United States Patent and Trademark Office, General Information Concerning
Patents, http://www.uspto.gov/go/pac/doc/general/#nature (last visited Sept. 27, 2009)
(stating that patent protection refers to the right to exclude others from making, using,
offering for sale or selling or importing the invention).
313
Royal Typewriter Co. v. Remington Rand, Inc., 168 F.2d 691, 692 (2d Cir. 1948).
314
Id.
315
Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722, 731 (2002).
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III. COME TOGETHER: THE UNITED STATES SHOULD MAINTAIN THE
CURRENT BALANCE INHERENT IN PATENT LAW AND NOT SACRIFICE
HEALTH FOR SPEEDY PRICE COMPETITION
Congress should implement key changes to the Hatch-Waxman
Act to monitor and address the primary concern of health. While
Congress has written and evaluated many bills, it has not found a
solution that opposing sides can agree upon. It is imperative that
the urgency of supplying cheaper biologics does not supersede the
requirement for safe and effective medication. The long-term goal
is for innovative research to maintain incentives to bring lifesaving biologics to Americans; without this incentive, Americans
will ultimately be the losers.
A. The Lines of Communication Are Open
A passable bill “should adequately compensate generic
manufacturers by providing at least some exclusivity for biologic
products.”316 All of the proposed Congressional bills had
drawbacks, either because they had too much exclusivity (House
Bill 1038 and Senate Bill 1695) or did not have any (House Bill
1956),317 and consequently, these bills were not passed.318 Until
there is a thoughtful conversation between both of these
approaches, the innovative pharmaceutical companies will enjoy a
market without competition from follow-on biologics.319
Considering that both innovative and generic pharmaceutical
companies have an interest in maximizing gross revenue, it is
encouraging that a thoughtful bipartisan discussion has already
ensued via the 110th Congress.320
The writers of the Eshoo Bill have considered many points of
contention from the previous 110th Congress and have softened

316

Kelleher, supra note 43, at 262.
See supra text accompanying notes 252–61.
318
See supra text accompanying note 262.
319
See Waxman, supra note 137.
320
Orrin G. Hatch, U.S. Sen., Now is the Time to Act: The Urgent Need to Pass S.
1695 in the 110th Congress (Sept. 22, 2008), http://www.biosimilarstoday.com/
2008/Hatch.pdf.
317
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the bill’s stance accordingly.321 An interesting twist in the Eshoo
Bill is that experimentation is not required, as this bill states that it
could be waived.322 It seems as though the 110th Congress’s
struggle with this issue can be shelved because of this concession.
The most hotly contested issue of the upcoming 111th Congress
will be the exclusivity provision.323 There is a large discrepancy
between five or twelve years of exclusivity, and negotiation to
reach a term will not be easy. The longer term of exclusivity
provides the ability for follow-on biologic companies to follow
through with additional experimentation,324 a possibility that would
not exist if the five-year exclusivity term were adopted. Thus, the
writers of the Eshoo Bill have already taken into consideration the
lessons of the 110th Congress and have made the concession of
mandatory experimentation. Any additional concession of the
Eshoo Bill, specifically the exclusivity of innovative biologics,
would drastically undermine consumer safety.
B. Consumer Safety
Generic pharmaceutical companies’ strong interest in creating
affordable biologics can be one-sided, in both the short and longterm. By not being subject to the standard testing procedures, the
follow-on biologic could adversely affect patients.325 Thus, by not
requiring additional experimentation, we are undermining the
public’s need for safe medicine.
Additionally, innovative
companies producing these pioneer biologics would not profit

321

Kurt R. Karst, FDA Law Blog, Rep Eshoo Proposes Draft Biogenerics Bill (Feb. 18,
2000),
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2009/03/rep-eshoointroduces-followon-biologics-bill-proposed-pathway-for-biosimilars-act-is-reportedlysimi.html. Rep. Anna Eshoo (D-CA), Rep. Jay Inslee (D-WA) and Rep. Joe Barton (RTX) are the authors of the Eshoo Bill.
322
Karst, supra note 321.
323
See supra note 251 and accompanying text.
324
See supra text accompanying notes 209–14.
325
See Corbitt, supra note 7, at 397–98 (“Executives from large pharmaceutical
corporations . . . have testified before congressional committees and cited public health
and safety as a reason to halt the approval of an expedited approval process for
biosimilars. They claim that there is no possible way to exactly and safely copy their
results.”).
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nearly as much as they would have in the past.326 As a result, those
companies will have less incentive to invest in cutting-edge
research to develop new, potentially life-saving medicines.327 If
Congress does not strike a balance between innovative and followon biologics, then the public is at risk to receive dangerous followon biologics, and innovative pharmaceutical companies will not
have the resources to invest into research and development.
Considering that both the Waxman Bill and Eshoo Bill have
compromised on the requirement of additional experimentation for
follow-on biologics, exclusivity is the next obvious issue of
contention. Since companies generating follow-on biologics
would be able to cut years off of the process of getting biologic
products to store shelves,328 these companies would surely want
shorter periods of innovative drug exclusivity. A short five-year
period of exclusivity is not desirable because it would undermine
the possibility of additional experimentation that the Eshoo Bill
provides.329 A longer period of exclusivity is crucial, as the Eshoo
Bill suggests, because this Bill innately provides additional time
for the follow-on manufacturer to test its biological product. In
this way, Congress can better achieve consumer health and safety
in both the short and long-term.
C. Preservation of Incentives for Innovative Drug Companies
An underlying priority must be to promote continued research
and development in the fields of biotechnology. Thus, American
patents must be strong and reliable, protecting the intellectual
property that they breed. If American patents are not as strong as
foreign patents or if there is significant uncertainty as to how
326

See id. at 390–91 (proposing that production of biosimilars may not be economically
efficient because its development costs are much higher than the development costs of a
small-molecule generic); see also Scherer, supra note 283, at 103–06 (“[M]ost [new
products] achieve much lower sales. . . . [N]ew drug development resembles a risky
lottery that throws out rich rewards to a few big winners while the majority of entries lose
money.”).
327
Corbitt, supra note 7, at 390–91.
328
Press Release, Federal Trade Commission, FTC Releases Report on “Follow-on
Biologic Drug Competition” (June 10, 2009), http://www.ftc.gov/opa/2009/06/biologics.
shtm.
329
H.R. 1427, 111th Cong. (2009).
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inventors will interpret American patents, inventors will quickly
lose incentive to continue filing in the United States. Thus,
protecting innovation by approving patents for biologics is
mandatory for continued industry and research growth.330
The example of insulin331 highlights why patent protection is
so important for biological research, as it took almost twenty years
for Eli Lilly to purify insulin and successfully obtain approval to
market this therapy.332 If the leaders within Eli Lilly knew that
their purified insulin would ultimately never receive patent
protection, they may not have invested almost two decades of
research in this field. Additionally, Eli Lilly may not have pursued
purification of naturally occurring biological proteins if their patent
rights were abbreviated and if they knew that generics would
immediately compete with their twenty years of hard work and
investment.
A final issue that needs to be addressed is whether abbreviating
the period of patent protection is an unconstitutional taking without
just compensation.333
Permitting pharmaceutical companies
manufacturing generics to take and use the discoveries of
innovative pharmaceuticals presents a strong argument for an
unconstitutional taking.334 Considering that huge amounts of
money are invested by brand-name pharmaceuticals for research
and development, there needs to be some reasonable compensation
for the discoveries.
CONCLUSION
The Biologics Act of 2007 first attempted to mold the HatchWaxman Act into a vehicle previously encompassing tiny, simple
drugs into an extension for large, complex biological molecules.335
330

Corbitt, supra note 7, at 400.
“Deducing the steps required to purify and produce insulin, for example, took
considerable work by some of the top scientists in the field.” Id. at 402.
332
Id.
333
Id.
334
See Monsanto Co. v. Acting Admin. U.S. EPA, 564 F. Supp. 552, 566–67 (E.D. Mo.
1983) (holding that the government attempted an unconstitutional taking of an innovator
manufacturer’s property right when requiring information held in trade secret).
335
See supra text accompanying notes 137–44.
331
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However, the question remains whether applying the Biosimilars
Act to the established Hatch-Waxman process of approval and
generic manufacture would be beneficial. The past and current
bills seek that generic biologics manufacturers satisfy further
requirements, such as conducting extensive clinical studies, which
will increase the biosimilar’s costs and decrease the margin
between the price of the innovative biologic and the follow-on
generic.336 Both bills have been referred to the House Energy and
Commerce Committee and the House Judiciary Committee.337
An additional concern, besides higher manufacturing costs and
decreased profits, is the actual market for follow-on biologics.
Doctors and patients alike have reservations about using generic
drugs in place of brand-name drugs. There is no way to predict
how follow-on biologics will be accepted by the general public;
will follow-on biologics be embraced as cheaper alternatives, or
will they be rejected because of potential health concerns? Passing
the Eshoo Bill or the Waxman Bill will answer this lingering
question. Because of these concerns, it is unclear whether the
follow-on biologic market will be as robust a competitor as the
generic small-molecule market. Clearly, if a follow-on biologic
market broadens due to the passing of the Biologics Act, it is of the
utmost importance that these generic biological medicines are safe
for consumer use. Therefore, it is in the best interest of consumers
to demand experimentation. Experimentation requires time, and
the Eshoo Bill provides this needed time. The Eshoo Bill carefully
and clearly lays out the regulation of biosimilars, additionally
leaving room for variation in experimentation requirements. The
Eshoo Bill best anticipates the needs of the American people and
must be voted for in the upcoming 111th Congress.

336

See supra notes 195–216 and accompanying text; see also H.R. 1427, 111th Cong.
(2009).
337
H.R. 1548, 111th Cong. (2009).

